Navigation Links
Life Technologies to Provide Ion Torrent Sequencing Platform to Quest Diagnostics for Development of New Molecular Tests
Date:1/9/2014

CARLSBAD, Calif., Jan. 9, 2014 /PRNewswire/ -- Life Technologies (NASDAQ: LIFE) has completed a multi-year license and supply agreement with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent™ next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently develop new tests for numerous areas of their business. 

DNA sequencing is a process that determines the order of individual nucleotides of DNA molecules across a single gene, several genes or a full genome. Unlike older technologies, next-generation sequencing (NGS) platforms can sequence multiple molecules simultaneously, providing greater information about the genetic basis of disease for lower cost. Ion Torrent™ technology combines speed and reliability with the ability to analyze large, multi-gene DNA or RNA panels from extremely small samples, such as those obtained from needle aspirates, circulating nucleic acids and circulating tumor cells.

"Next-generation sequencing is a highly advanced technology with great potential to improve clinical care, research and cost savings across several fields of medicine," said Jay Wohlgemuth, M.D., Senior Vice President, Science and Innovation, Quest Diagnostics. "Quest is actively developing NGS-based tests and working with top providers, such as Life Technologies, to expand our capabilities in this exciting new field. With this agreement, we can build on our successes in NGS to accelerate the future clinical benefit and positive impact of this technology for patients and providers across several disease areas, including cancer, neurology and women's health."

This new agreement extends the range of applications in which Quest may develop tests on the Ion Torrent technology to more than a dozen.

"The power of next-generation sequencing technology is transforming healthcare by giving physicians an opportunity to understand disease at the molecular level," said Ronnie Andrews, president, Genetic Analysis and Medical Science at Life Technologies. "Quest Diagnostics is a pioneer at bringing new technologies into the clinic through their centers of excellence and is the ideal partner to leverage the potential of Ion Torrent™ technology to improve human health."

The regulatory status of Ion Torrent products can be found on the Life Technologies website.

About Life Technologies 
Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement 
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact:
Wes Conard
415-385-4455
wes.conard@lifetech.com 


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ISTO Technologies Appoints James McGorry to Board of Directors
2. Patient Safety Technologies, Inc. Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $2.22 Per Common Share in Cash
3. BioSpecifics Technologies Corp. Announces Top-line Data from Phase 2 Trial of CCH for Canine Lipoma
4. Global Algae Biofuel Technologies Market 2014-2018 with a CAGR of 43.4 Percent for the Period 2013–2018
5. IROA Technologies automates metabolic profiling with launch of labeling and software kits
6. Smart Imaging Technologies and InvitroCue Team Up to Bring Digital Pathology to Asia
7. New venue, new conference, new courses, new technologies for Electronic Imaging 2014
8. Ancon Technologies New Cancer Screening Technology Will Help Defeat Cancer
9. United Technologies plans $10 million investment for UConn systems engineering institute
10. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
11. Great Lakes NeuroTechnologies Awarded Patent For Sensor Based Continuous Parkinsons Assessment During Daily Activities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):